Novo Nordisk presented a 52-week fMRI study showing the investigational drug CagriSema altered brain responses to food cues. Read our analysis of the data.
On September 30, 2026, Novo Nordisk announced findings from a 52-week functional MRI study regarding an investigational obesity treatment. According to the company press release, the research examined how an experimental medication called CagriSema influenced brain responses to high-calorie food cues in adults with overweight or obesity. The data was presented as a late-breaking abstract at the European Association for the Study of Diabetes Annual Meeting 2026. The announcement identifies the research team as Uhre VF, Alex M, Bak N, and colleagues.
The presentation received a Best Abstract Award at the scientific conference, drawing attention to its focus on neurological responses. The study attempts to measure subjective experiences like cravings using objective medical imaging technology. By monitoring brain activity over a full year, researchers aimed to map the biological pathways associated with human appetite.
The findings may be relevant to adults who experience persistent hunger, intense cravings, or a daily preoccupation with food. The study suggests these experiences are now being measured objectively in research on weight-management treatments. They are no longer being treated simply as a failure of willpower or a lack of personal discipline. This shift in scientific focus represents a meaningful change in how researchers approach chronic metabolic conditions.
CagriSema is described by Novo Nordisk as an investigational, once-weekly combination medication. It combines cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist. These two components target distinct physiological pathways that regulate appetite and metabolic function. By combining them, scientists aim to influence multiple hormonal receptors responsible for human energy balance.
This dual-action approach represents a new phase in metabolic research, moving beyond treatments that target only a single hormone. The scientific community is increasingly interested in how combining agonists might produce different outcomes than individual therapies. Investigating these complex interactions requires precise measurement tools like functional magnetic resonance imaging. Such advanced imaging provides researchers with a window into the biological mechanisms that drive human behavior.
The 52-week functional MRI study observed human brain activity by tracking blood flow changes in real time. Researchers monitored how the brains of participants reacted when they looked at pictures of high-calorie foods. The findings reported altered brain responses in specific neural regions linked to energy intake. These specific regions are associated with sensory processing, behavioral control, reward anticipation, and cravings.
When we discuss the neuroscience of food noise, we are looking directly at these complex neurological pathways. The conference findings suggest that persistent cravings are rooted in physical brain activity rather than a simple lack of willpower. Weight management outcomes are heavily influenced by these internal biological signals, alongside nutrition, sleep, and environmental factors. By targeting amylin and GLP-1 receptors simultaneously, the treatment attempts to moderate how the central nervous system processes visual food cues.
Mainstream health media often treats early medication announcements as definitive medical facts. However, the information presented at the European Association for the Study of Diabetes remains a conference abstract. It has not yet been published as a full, peer-reviewed medical paper. Novo Nordisk did not provide the fMRI study sample size, medication dose, or confidence intervals in their public announcement.
The lack of group-level weight results and a formal statistical model limits the ability of independent researchers to evaluate the findings. Without these critical details, the scientific community cannot confirm the precision or clinical reliability of the reported outcomes. The press release was issued directly by Novo Nordisk, the developer of the investigational medication. Therefore, these results warrant cautious interpretation until independent replication is entirely possible.
Without independent validation, the clinical community cannot fully endorse the findings presented in a preliminary conference setting. Transparency regarding statistical models and group-level weight results is essential for determining true therapeutic efficacy. A company-reported abstract is simply the first step in a long process of scientific peer review. Patients and providers must wait for the complete data before making informed decisions about new metabolic interventions.
Furthermore, observing changes in food-cue brain responses alongside a weight reduction does not establish a direct cause and effect. The available clinical coverage explicitly notes that the fMRI findings do not prove that altered brain responses caused the weight changes. Brain imaging shows a correlation, but human metabolism involves many intersecting and complex biological systems. We must view these company-reported observations as preliminary evidence rather than a final scientific consensus.
The conference presentation detailed several reported clinical observations recorded at week 22 and week 52 of the trial. Novo Nordisk reported significant improvements in subjective eating behaviors among the adult study participants. These reported improvements included less hunger, reduced appetite, fewer food-related thoughts, and decreased overall food noise. Participants also demonstrated improved craving control across the entire duration of the trial.
Regarding physical weight outcomes, the company reported an estimated 22.4 percent treatment difference in body weight versus a placebo at week 52. The announcement noted a statistical significance of p<0.0001 for this estimated body weight difference. It is important to emphasize that this figure is a company-reported estimated difference versus placebo. It should not be interpreted as a simple within-group weight-loss percentage guaranteed for every individual patient.
The distinction between a company-estimated treatment difference and actual observed weight loss is critical for accurate health communication. An estimated difference compares the active treatment group to a placebo group using specific statistical models. It does not mean that every participant in the trial automatically lost twenty-two percent of their body weight. Clear science translation requires us to interpret these estimates with careful attention to the underlying study design.
The announcement also described separate conference analyses that should not be confused with the primary fMRI study. A distinct MRI sub-study in adults with early type 2 diabetes reported a 14.3 percent weight reduction at week 40. That specific sub-study also reported reduced abdominal, liver, and pancreatic fat. Finally, a separate post hoc bone-marker analysis reported findings that the authors themselves characterized as preliminary.
Historically, clinical research focused almost exclusively on scale weight and standard metabolic blood panels. The inclusion of subjective markers like craving control indicates an evolving understanding of comprehensive metabolic health. When patients report persistent preoccupation with food, it actively affects their daily quality of life and routine habits. Measuring these behavioral markers provides a much clearer picture of how investigational therapies interact with human psychology.
These behavioral measurements validate that understanding the causes of food cravings is a necessary step in sustainable weight management. However, the reported results do not guarantee that the investigational treatment will work for every single individual. They also do not prove that the reported effects on appetite will persist after the trial period ends. Medication alone cannot replace the foundational elements of healthy living, including consistent sleep, daily movement, and balanced nutrition.
Managing your environment remains critical, especially when weight-loss medications fail to stop cravings entirely. Sustainable health requires ongoing behavioral support that adapts to your unique daily life. An investigational therapy might alter brain responses, but the patient still has to navigate complex social eating environments. This is why a holistic approach to behavior change is always required for long-term success.
The human appetite is a complicated system that involves psychological habits, physical environments, and deep biological drives. Recognizing the biological component of food noise helps to remove the shame often associated with chronic weight management. However, patients must still develop practical strategies for managing their daily food environments and coping with stress. The most effective interventions will likely combine medical therapies with comprehensive behavioral education.
Novo Nordisk submitted an obesity New Drug Application for CagriSema to the U.S. FDA in December 2025. The manufacturer stated that it expected an FDA decision regarding the treatment in the fourth quarter of 2026. Until regulatory bodies issue a final ruling, the medication remains completely investigational. It is not currently available for clinical prescription or general public use.
Future research must publish the complete fMRI study data in an independent, peer-reviewed medical journal. Scientists need to see a transparent reporting of the sample size, medication dosing, and statistical confidence intervals. Clarifying these variables is absolutely necessary before this experimental therapy can become a standard clinical practice. WeightRestart will continue to monitor these developments to provide clear, factual updates on emerging metabolic treatments.
The regulatory review process is designed to thoroughly evaluate the safety, efficacy, and tolerability of new medical compounds. The U.S. FDA will assess the complete clinical trial data, including any side effects or long-term risks associated with the treatment. Patients should consult their healthcare providers regarding currently approved options rather than waiting for investigational therapies to clear regulatory hurdles. The landscape of metabolic medicine is evolving rapidly, and rigorous scientific oversight remains our best tool for ensuring patient safety.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
